Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy



Status:Completed
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:5/6/2016
Start Date:October 2011
End Date:July 2015

Use our guide to learn which trials are right for you!

A Phase II, Open-Label, Randomized Study of GDC-0980 Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following VEGF-Targeted Therapy

Study PIM4973g is a multicenter, international, open-label Phase II trial. Participants with
metastatic renal cell carcinoma who have progressed on or after VEGF targeted therapy will
be randomized in 1:1 to two groups either to receive daily GDC-0980 or everolimus orally.


Inclusion Criteria:

- Histologically or cytologically documented, incurable metastatic renal cell carcinoma
with clear-cell component that progressed on or within 6 months of stopping
VEGF-targeted therapy

- Disease that is measurable per Response Evaluation Criteria in Solid Tumors Version
1.1 (RECIST v1.1)

- Karnofsky performance status of greater than or equal to (>=) 70 percent (%)

- Adequate hematologic and end organ function

- For female participants of childbearing potential and male participants with partners
of childbearing potential, agreement to use two effective forms of contraception and
to continue its use for the duration of the study

Exclusion Criteria:

- Any anti-cancer therapy, including chemotherapy, biologic or other targeted therapy,
herbal therapy, hormonal therapy, or radiotherapy, within 5 half-lives (for systemic
agents) or 2 weeks, whichever is shorter, prior to Day 1. Certain forms of radiation
therapy may be considered for pain palliation if participants are deriving benefit

- Previously established diagnosis of pulmonary fibrosis of any cause

- New York Heart Association (NYHA) Class II or greater congestive heart failure

- History of malabsorption syndrome or other condition that would interfere with
enteral absorption

- Presence of positive test results for hepatitis B (hepatitis B [HB] surface antigen
[HBsAg] and/or total HB core antibody [anti-HB-c; both tests are required]) or
hepatitis C

- Known human immunodeficiency virus (HIV) infection

- Pregnancy, lactation, or breastfeeding

- Major surgical procedure or significant traumatic injury within 28 days prior to Day
1 or anticipation of the need for major surgery during the course of study treatment

- Leptomeningeal disease as a manifestation of cancer

- History of other malignancies less than equal to <= 5 years of Day 1 except for
tumors with a negligible risk for metastasis or death, such as adequately controlled
basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of
the cervix

- Need for current chronic corticosteroid therapy (>= 10 milligrams [mg] of prednisone
per day or an equivalent dose of other anti-inflammatory corticosteroids for greater
than [>] 7 days) or use of other immunosuppressant
We found this trial at
9
sites
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
Bordeaux,
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
Saint Petersburg, Florida 33713
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials